BioLeap > About

Overview

BioLeap is a molecule discovery and design company driven by proprietary, next-generation computational fragment-based molecule design (CFBMD) technology. We create new chemical entities, molecularly tailored to modulate a particular biological process.

BioLeap changes the paradigm for identifying chemical starting points and for deciding which compounds to make next during lead optimization, obviating the need for costly high throughput screening (HTS) or synthetic chemical tinkering.

BioLeap’s process creates novel compounds with intellectual property protection, enhances the intellectual property estate around existing compounds, avoids obstructive patents and generates fast-follower compounds for early market entry.

Unlike random screening approaches, BioLeap’s hypothesis-driven method is particularly effective for designing and improving lead compounds for ‘difficult’ targets where traditional methods have failed.